2-aminopyrimidine compound and pharmaceutical composition thereof and application thereof

2-aminopyrimidine compounds with the structure shown in Formula (I) or their pharmaceutically acceptable salts, solvates, or their stereoisomers, geometric isomers, tautomers:

• wherein,
• R1 is selected from:
• H, halogen, cyano, a C1-C6 alkyl group optionally substituted with one or more R11 groups, a C3-C6 cycloalkyl group optionally substituted with one or more R1 groups, a C1-C6 alkoxy group optionally substituted with one or more R11 groups, a C3-C6 cycloalkoxy group optionally substituted with one or more R11 groups, —NH—C(═O)H;
• R2 is selected from:
• H, halogen, —(CH2)mNR3R4, —(CH2)mCR3R4R5 or —(CH2)mOCR3R4R5;
• wherein, each m is independently 0, 1, 2, or 3;
• each R3 and each R4 are independently selected from:
• (i) H, or one or more R12 substituted C1-C6 alkyl groups;
• and (ii) R3 and R4, together with the attached N or C, may form a 3-12 membered single ring, fused ring, bridge ring, or spiral ring containing 0-3 heteroatoms and optionally substituted with one or more R12 groups;
• R5 is selected from:
• H, cyano or C1-C3 alkyl;
• each R12 is independently selected from:
• H, halogen, hydroxyl, amino, C1-C3 alkyl, C1-C3 alkyl substituted by —C(═O)NHR13, hydroxy substituted C1-C3 alkyl, C1-C3 alkyl substituted by C3-C6 cycloalkyl group, C3-C8 heterocyclic group substituted C1-C3 alkyl group, C1-C3 alkoxy, —NHR13, —N(R13)2, —C(═O)R13, R13 substituted or unsubstituted 4-8-membered single ring, fused ring, bridge ring, or spiral ring containing 0, 1, 2, or 3 heteroatoms;
• R13 is a C1-C3 alkyl group;
• the heteroatom is O, S, and/or N;
• W, X, Y, and Z are independently N or —CR6;
• wherein, R6 is selected from:
• hydrogen, halogen, a C1-C3 alkyl group optionally substituted with one or more R11 groups, a C1-C3 alkoxy group optionally substituted with one or more R11 groups, —NH—CN, —NHC(O)—CR7═CR8R9, —NHS(O)2—CR7=CR8R9;
• R7, R8, and R9 are independently selected from:
• H, cyano, a C1-C6 alkyl group optionally substituted with one or more R11 groups;
• n is 1;
• L is 0 or S;
• is a 8-10 membered saturated or partially saturated fused double ring containing 1, 2, or 3 oxygen atoms and optionally substituted with one or more R10 groups;
• wherein, each R10 is independently selected from:
• hydrogen, halogen, hydroxyl, a C1-C3 alkyl group optionally substituted with one or more R11 groups, a C1-C3 alkoxy group optionally substituted with one or more R11 groups,
• R11 is selected from:
• halogen, hydroxyl, amino, C1-C3 alkyl, C1-C3 alkoxy, —NHR13, —N (R13)2, —C(═O) R3.